Cingulate Inc (CING) Receives a Hold From Maxim Group
TipRanksApr 4 11:05 ET
Cingulate Analyst Ratings
BenzingaJan 5 07:40 ET
Laidlaw Cuts Cingulate to Hold, Cites Dwindling Resources
Seeking AlphaDec 22, 2023 16:15 ET
Cingulate Analyst Ratings
BenzingaDec 22, 2023 04:40 ET
Cingulate Analyst Ratings
BenzingaDec 19, 2023 09:47 ET
Cingulate Analyst Ratings
BenzingaDec 18, 2023 11:36 ET
Cingulate Inc's Strong Financial Position and Promising ADHD Drug Development Prospects Garner Buy Rating From Maxim Group
TipRanksNov 16, 2023 15:45 ET
Analysts Offer Insights on Healthcare Companies: Cano Health (CANO), Personalis (PSNL) and Cingulate Inc (CING)
TipRanksOct 25, 2023 06:20 ET
HC Wainwright & Co. Maintains Buy on Cingulate, Lowers Price Target to $3.5
BenzingaSep 26, 2023 06:27 ET
Cingulate Analyst Ratings
BenzingaSep 26, 2023 06:25 ET
Analysts Are Bullish on Top Healthcare Stocks: Cingulate Inc (CING), Achieve Life Sciences (ACHV)
TipRanksJul 13, 2023 07:40 ET
Maxim Group Reaffirms Their Buy Rating on Cingulate Inc (CING)
TipRanksJun 9, 2023 10:35 ET
Maxim Group Remains a Buy on Cingulate Inc (CING)
TipRanksMay 12, 2023 10:25 ET
Maxim Group Keeps Their Buy Rating on Cingulate Inc (CING)
TipRanksMay 5, 2023 10:56 ET
Maxim Group Keeps Their Buy Rating on Cingulate Inc (CING)
TipRanksFeb 25, 2023 07:41 ET
Cingulate Analyst Ratings
Benzinga Analyst RatingsJan 17, 2023 06:23 ET
HC Wainwright & Co. Initiates Coverage On Cingulate With Buy Rating, Announces Price Target of $5.5
Benzinga Real-time NewsJan 17, 2023 06:23 ET
Maxim Group Remains a Buy on Cingulate Inc (CING)
TipRanksDec 8, 2022 15:10 ET
Maxim Starts Cingulate at Buy With $3 Price Target
MT NewswiresNov 22, 2022 09:43 ET
Cingulate Analyst Ratings
Benzinga Analyst RatingsNov 22, 2022 08:22 ET
No Data
No Data